Kuehn Law Encourages Investors of Agenus Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - February 4, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Agenus Inc. (NASDAQ: AGEN) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Agenus insiders caused the company to misrepresent or fail to disclose that (i) the combination therapy of botensilimab and balstilimab was less effective than represented; (ii) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you currently own AGEN and purchased prior to January 23, 2023 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239574